Literature DB >> 29438108

STAT3-enhancing germline mutations contribute to tumor-extrinsic immune evasion.

Daniel Kogan1,2, Alexander Grabner3, Christopher Yanucil4, Christian Faul4, Vijay Kumar Ulaganathan5.   

Abstract

Immune evasion and the suppression of antitumor responses during cancer progression are considered hallmarks of cancer and are typically attributed to tumor-derived factors. Although the molecular basis for the crosstalk between tumor and immune cells is an area of active investigation, whether host-specific germline variants can dictate immunosuppressive mechanisms has remained a challenge to address. A commonly occurring germline mutation (c.1162G>A/rs351855 G/A) in the FGFR4 (CD334) gene enhances signal transducer and activator of transcription 3 (STAT3) signaling and is associated with poor prognosis and accelerated progression of multiple cancer types. Here, using rs351855 SNP-knockin transgenic mice and Fgfr4-knockout mice, we reveal the genotype-specific gain of immunological function of suppressing the CD8/CD4+FOXP3+CD25+ regulatory T cell ratio in vivo. Furthermore, using knockin transgenic mouse models for lung and breast cancers, we establish the host-specific, tumor-extrinsic functions of STAT3-enhancing germline variants in impeding the tumor infiltration of CD8 T cells. Thus, STAT3-enhancing germline receptor variants contribute to immune evasion through their pleiotropic functions in immune cells.

Entities:  

Keywords:  Complex traits; Genetic variation; Genetics; Homeostasis; Oncology

Mesh:

Substances:

Year:  2018        PMID: 29438108      PMCID: PMC5919827          DOI: 10.1172/JCI96708

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  26 in total

1.  dbSNP: the NCBI database of genetic variation.

Authors:  S T Sherry; M H Ward; M Kholodov; J Baker; L Phan; E M Smigielski; K Sirotkin
Journal:  Nucleic Acids Res       Date:  2001-01-01       Impact factor: 16.971

2.  Lung-targeted expression of the c-Raf-1 kinase in transgenic mice exposes a novel oncogenic character of the wild-type protein.

Authors:  E Kerkhoff; L M Fedorov; R Siefken; A O Walter; T Papadopoulos; U R Rapp
Journal:  Cell Growth Differ       Date:  2000-04

Review 3.  Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment.

Authors:  Hua Yu; Marcin Kortylewski; Drew Pardoll
Journal:  Nat Rev Immunol       Date:  2007-01       Impact factor: 53.106

Review 4.  The Basis of Oncoimmunology.

Authors:  A Karolina Palucka; Lisa M Coussens
Journal:  Cell       Date:  2016-03-10       Impact factor: 41.582

5.  Inhibition of mammary gland involution is associated with transforming growth factor alpha but not c-myc-induced tumorigenesis in transgenic mice.

Authors:  E P Sandgren; J A Schroeder; T H Qui; R D Palmiter; R L Brinster; D C Lee
Journal:  Cancer Res       Date:  1995-09-01       Impact factor: 12.701

6.  Foxp3-deficient regulatory T cells do not revert into conventional effector CD4+ T cells but constitute a unique cell subset.

Authors:  Michal Kuczma; Robert Podolsky; Nikhil Garge; Danielle Daniely; Rafal Pacholczyk; Leszek Ignatowicz; Piotr Kraj
Journal:  J Immunol       Date:  2009-08-26       Impact factor: 5.422

7.  A single nucleotide change in the mouse genome accelerates breast cancer progression.

Authors:  Nina Seitzer; Thomas Mayr; Sylvia Streit; Axel Ullrich
Journal:  Cancer Res       Date:  2010-01-12       Impact factor: 12.701

Review 8.  Hallmarks of cancer: the next generation.

Authors:  Douglas Hanahan; Robert A Weinberg
Journal:  Cell       Date:  2011-03-04       Impact factor: 41.582

9.  COSMIC: exploring the world's knowledge of somatic mutations in human cancer.

Authors:  Simon A Forbes; David Beare; Prasad Gunasekaran; Kenric Leung; Nidhi Bindal; Harry Boutselakis; Minjie Ding; Sally Bamford; Charlotte Cole; Sari Ward; Chai Yin Kok; Mingming Jia; Tisham De; Jon W Teague; Michael R Stratton; Ultan McDermott; Peter J Campbell
Journal:  Nucleic Acids Res       Date:  2014-10-29       Impact factor: 16.971

10.  A global reference for human genetic variation.

Authors:  Adam Auton; Lisa D Brooks; Richard M Durbin; Erik P Garrison; Hyun Min Kang; Jan O Korbel; Jonathan L Marchini; Shane McCarthy; Gil A McVean; Gonçalo R Abecasis
Journal:  Nature       Date:  2015-10-01       Impact factor: 49.962

View more
  6 in total

Review 1.  FGFR4: A promising therapeutic target for breast cancer and other solid tumors.

Authors:  Kevin M Levine; Kai Ding; Lyuqin Chen; Steffi Oesterreich
Journal:  Pharmacol Ther       Date:  2020-05-31       Impact factor: 12.310

Review 2.  Germline Variants Impact Somatic Events during Tumorigenesis.

Authors:  Johnny R Ramroop; Madelyn M Gerber; Amanda Ewart Toland
Journal:  Trends Genet       Date:  2019-05-22       Impact factor: 11.639

3.  N6-methyladenosine regulated FGFR4 attenuates ferroptotic cell death in recalcitrant HER2-positive breast cancer.

Authors:  Yutian Zou; Shaoquan Zheng; Xinhua Xie; Feng Ye; Xiaoqian Hu; Zhi Tian; Shu-Mei Yan; Lu Yang; Yanan Kong; Yuhui Tang; Wenwen Tian; Jindong Xie; Xinpei Deng; Yan Zeng; Zhe-Sheng Chen; Hailin Tang; Xiaoming Xie
Journal:  Nat Commun       Date:  2022-05-13       Impact factor: 17.694

Review 4.  Coordinated regulation of immune contexture: crosstalk between STAT3 and immune cells during breast cancer progression.

Authors:  Jing Jin; Yi Li; Qijie Zhao; Yue Chen; Shaozhi Fu; JingBo Wu
Journal:  Cell Commun Signal       Date:  2021-05-06       Impact factor: 5.712

5.  MicroRNA-325-3p Facilitates Immune Escape of Mycobacterium tuberculosis through Targeting LNX1 via NEK6 Accumulation to Promote Anti-Apoptotic STAT3 Signaling.

Authors:  Beibei Fu; Weiwei Xue; Haiwei Zhang; Rui Zhang; Kelly Feldman; Qingting Zhao; Shanfu Zhang; Lei Shi; Krishna Chaitanya Pavani; Weiqi Nian; Xiaoyuan Lin; Haibo Wu
Journal:  mBio       Date:  2020-06-02       Impact factor: 7.867

Review 6.  Dissecting the Role of the FGF19-FGFR4 Signaling Pathway in Cancer Development and Progression.

Authors:  Yanan Liu; Meng Cao; Yuepiao Cai; Xiaokun Li; Chengguang Zhao; Ri Cui
Journal:  Front Cell Dev Biol       Date:  2020-02-20
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.